Recent progress in targeted therapies, both in adjuvant and metastatic settings, has improved the prognosis of ER-positive and HER2-positive breast cancers, whereas the improvement in survival has currently plateaued for TNBC [1]. The gene discussed is ESR1; the disease is breast carcinoma.